Exclusive Rights, Episode 2: United States Signifies Approval of Intellectual Property Waiver for COVID-19 Vaccines – Intellectual Property
United States: Exclusive Rights, Episode 2: United States Signifies Approval of Intellectual Property Waiver for COVID-19 Vaccines
To print this article, simply register or connect to Mondaq.com.
In this episode of our exclusive rights podcast series, Mintz IP attorneys Daniel Weinger and Todd B. Buck, PhD, discuss the Biden administration’s recent decision to signal U.S. approval of a proposed waiver of intellectual property rights related to COVID-19 vaccines currently. under review at the World Trade Organization (WTO). India and South Africa first proposed the controversial intellectual property rights waiver last year, and the United States had not previously supported such waivers. Dan and Todd discuss the importance of White House communication and the impact such a waiver could have on businesses.
Their discussion focuses on the following questions:
- Impact of the General Intellectual Property Waiver
- Does the waiver help meet the stated goal of increased access to vaccines?
- Potential industry responses to a major shift in US policy
- Non-IP roadblocks that remain even if the waiver takes effect
- Possible and already existing alternative solutions via the TRIPS provision of the WTO
Click here to listen to the podcast.
The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought on your particular situation.
POPULAR ARTICLES ON: United States Intellectual Property